Back to Search
Start Over
Targeting T Cell Malignancies Using CD4CAR T-Cells and Implementing a Natural Safety Switch.
- Source :
-
Stem cell reviews and reports [Stem Cell Rev Rep] 2019 Jun; Vol. 15 (3), pp. 443-447. - Publication Year :
- 2019
-
Abstract
- T cell malignancies are aggressive diseases with no standard treatment available, often resulting in poor patient outcomes. Lately, the recent FDA approval of a CD19 CAR T cell therapy for B cell acute lymphoblastic leukemia has earned nationwide attention, leading to the possibility that success of CD19 CAR therapy can be extended to T cell malignancies. However, the impact of T cell depletion due to a shared antigen pool remains an issue to be resolved. Here, we describe a CD4CAR capable of eliminating CD4-positive T cell acute lymphoblastic leukemia in a systemic mouse model, with CAMPATH (alemtuzumab) as a natural safety switch to deplete the infused CD4CAR T cells to prevent toxicities associated with CD4 cell aplasia. Our data support the potential use of CD4CAR T cells for the treatment of CD4-postive T-cell acute lymphoblastic leukemia malignancies or refractory disease in clinical settings.
- Subjects :
- Animals
Humans
Jurkat Cells
Male
Mice
Mice, Inbred NOD
Xenograft Model Antitumor Assays
Alemtuzumab pharmacology
CD4-Positive T-Lymphocytes pathology
CD4-Positive T-Lymphocytes transplantation
Immunotherapy, Adoptive
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma pathology
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma therapy
Subjects
Details
- Language :
- English
- ISSN :
- 2629-3277
- Volume :
- 15
- Issue :
- 3
- Database :
- MEDLINE
- Journal :
- Stem cell reviews and reports
- Publication Type :
- Academic Journal
- Accession number :
- 30826931
- Full Text :
- https://doi.org/10.1007/s12015-019-09876-5